A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

November 21, 2025

Primary Completion Date

December 5, 2028

Study Completion Date

June 18, 2030

Conditions

Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia

Interventions

DRUG

Blinatumomab

Blinatumomab will be administered as a SC injection for up to 5 cycles (each cycle will be 35 days).